Patients undergoing allogeneic hematopoietic stem cell transplant require variable, often extensive transfusion support. Identification of factors that predict urgent, intensive, or special needs should improve management of these patients.
CONCLUSION: Patient-specific factors including CD34+
dose and ABO match of the graft should be given particular consideration by transfusion services when planning support of patients receiving allogeneic hematopoietic stem cell transplant.
H ematopoietic stem cell transplant programs impose substantial and specialized challenges in clinical care [1] [2] [3] [4] [5] [6] and inventory manage- services. Patients undergoing hematopoietic stem cell transplantation (HSCT) experience differing periods of prolonged cytopenia, necessitating close monitoring and often requiring intensive, urgent, or specialized transfusion support. Further, individual patients may present unexpected and complex hematologic complications arising from their primary disease, their transplant regimen, and/or graft-host interactions. For transfusion services to provide optimal care, prior knowledge of patient factors that might predict special needs or the requirement for prolonged component support following transplantation is desirable, to facilitate individualized care planning and acquisition of dedicated blood component inventories in advance of need.
We quantified red blood cell (RBC) and platelet transfusion support, and the time course of these transfusions after HSCT, for a large group of human leukocyte antigen (HLA)-matched sibling donor (MSD) transplants performed at a single center. The relative importance of a few key baseline factors readily known to the transfusion medicine service, such as need for transfusions before transplant, the ABO match of the donor and recipient, the type of transplant regimen (myeloablative or nonmyeloablative), and the CD34+ stem cell dose, were analyzed. Patient-specific demographic and clinical factors including diagnosis, blood type, and disease stage were also studied.
MATERIALS AND METHODS

Protocol
Study protocol 13-CC-N026 was reviewed and approved by the Institutional Review Board (IRB) of the National Heart, Lung and Blood Institute, Clinical Center, National Institutes of Health (NIH). A waiver of written informed consent was approved for this retrospective natural history study.
Demographic and baseline data
Databases of the Department of Transfusion Medicine (DTM) and the Medical Record Department, NIH Clinical Center, were researched to identify a total of 800 sequential patients who received an HLA MSD HSCT on prospective clinical protocols at the Clinical Center, from 1993 through 2010 (Fig. S1 , available as supporting information in the online version of this paper). [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Subject baseline demographics are provided in Table 1A for all patients, and by transplant regimen in Table S1 (available as supporting information in the online version of this paper). The primary treatment protocols are listed by Institute in Appendix S1 (available as supporting information in the online version of this paper). Demographic and baseline data for each subject including age, gender, diagnosis, weight, subject ABO type, donor ABO type, category of transplant preparative regimen, date of graft infusion and CD34+ hematopoietic stem cell dose were obtained. For subject diagnoses and the categories used for this analysis, see Table S3 (available as supporting information in the online version of this paper). Transplant preparative regimen was specified by the subject's primary transplant protocol (Table S4 , available as supporting information in the online version of this paper). The need, if any, for transfusion of RBCs or platelets during Days −10 through −1 immediately preceding graft infusion was assessed as "none" (no transfusions) versus "any" (one or more transfusions 
Transfusion practices
Standard transfusion practices were followed, to maintain target hemoglobin(Hb)/hematocrit values and platelet counts. [1] [2] [3] [4] [5] [6] We note that transfusion medicine guidelines for patient hemoglobin and platelet counts evolved during 1993 through 2010, the period of this study. 
Quantity of transfusion support
RBC and platelets transfused were summed for each patient for each of the intervals 0 through 30, 0 through 100, and 101 through 200 days after transplantation ( 
Time to transfusion independence
Time to RBC transfusion independence, defined as the day of last transfusion preceding 30 days or more during which no transfusion of RBCs was needed, was determined for each subject. The same interval was designated for platelets, for convenience. The definition of 30 days or more was used, as an adult patient unable to produce RBCs and totally dependent on transfusion will require about 1 unit of RBCs per week.
Statistical analyses
Descriptive analyses of baseline data and quantity of transfusions after HSCT included mean and standard deviation for the number of RBC and platelet transfusions per patient, for groups of interest. Univariate statistical significance of the association between each baseline variable and transfusion quantity was assessed by analysis of variance (Table 2) . Linear regression models were built stepwise to determine which baseline predictors were jointly significant in their association with RBC transfusion support as well as with platelet transfusion support for each time interval (Table 3) . Analysis of every estimated effect was in comparison to a reference group we defined as having standard risk hematologic malignancy, needing no transfusions before HSCT, receiving a myeloablative peripheral blood stem cell (PBSC) transplant regimen and a large CD34+ dose, ABO identical with respect to recipient-donor, for a transplant procedure performed during 2006 through 2010. Time to transfusion independence was analyzed by Kaplan-Meier methods. Cox proportional hazards regression analysis was used to study the relative importance of baseline variables and covariates related to independence of transfusion support (Table 4) .
Because subgroup analyses on the many baseline variables of interest could lead to spurious findings, an alpha = 0.01 instead of 0.05 was used as a cutoff for statistical significance.
All analyses were performed using graphical software (SAS E-Guide Version 5.1 for Windows or original SAS programs developed for this study), using SAS Version 9.3 (SAS Institute).
RESULTS
MSD allogeneic HSCT at the Clinical Center, NIH (1993-2010)
From 1993 through 2010, 800 matched sibling transplants were performed continuously, with more cases per year for the years 1999 through 2005 than before or since ( Table S4 ) used lower doses of chemotherapy and/or radiotherapy, and some included components that were lymphoablative preferentially, to facilitate donor engraftment with fewer regimen-related toxicities. Grafts were collected by apheresis of donor peripheral blood CD34+ stem cells, after mobilization using growth factors. [15] [16] [17] [18] [19] Nonmyeloablative regimens are indicated as "PBSC Nonmyeloablative" procedures in Fig. S1C . While most of the group of 292 nonmyeloablative transplants (see Table 1 ) received regimens containing fludarabine and cyclophosphamide, we note that a cohort of 22 transplants performed for SCD (Protocol 03-DK-0170; see Appendix S1) received conditioning that included alemtuzumab and total body irradiation (see Table S4 ). During 1999, there were more nonmyeloablative than myeloablative transplants performed at the Clinical Center (Fig. S1C) . By 2000, nonmyeloablative transplants were about one-half of all procedures, and from 2001 through 2010, they were about one-third to somewhat less than one-third of all procedures. The regimen labeled "TLD + PBSC Nonmyeloablative" in Fig. S1C was a modified nonmyeloablative approach, in which patients with malignancies were pretreated with chemotherapy and T-cell-depleting agents to achieve targeted lymphocyte depletion (TLD) 20 prior to receiving a reduced intensity preparative regimen (Table S4) ; grafts were collected by apheresis of donor peripheral blood, after mobilization of CD34+ stem cells. [20] [21] [22] The numbers and relative
proportions of "TLD + PBSC Nonmyeloablative" procedures performed at the Clinical Center were reasonably consistent during 2000 through 2010.
Demographic and baseline clinical and laboratory data Age, sex, and weight
The distributions of subject age (mean, 41.6 years) and weight (mean 71.6 kg) were distributed normally (data not * All n = 800 subjects were considered available for the intervals 0 to 30 days, and 0 to 100 days. For the interval 101 to 200 days, the subset included those who completed at least one day in the interval. Patients became unavailable due to death or censoring because of a second transplant. Analysis of variance for patient age, or gender, or weight revealed no significance for RBC or platelets transfused. ANOVA = analysis of variance; HSCT = hematopoietic stem cell transplantation; NA = not applicable/not analyzed; PBSC = peripheral blood stem cell; RBC = red blood cell; TLD = targeted lymphocyte depletion.
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Diagnostic category
The categories (see Table S3 ) "Standard Risk Hematologic Malignancy" (n = 212), "Intermediate Risk Hematologic Malignancy" (n = 241), and "Solid Tumor" (n = 169) each had about 150 or more subjects enrolled, whereas the categories "High Risk Hematologic Malignancy" (n = 80) and "Benign Heme/Nonmalignant Hematologic Disorder" (n = 98) were less well represented (Table 1A) .
The distribution of diseases studied at the Clinical Center in any given year was necessarily dependent on the clinical trials being open and recruiting subjects. Thus, while we classified the indications for HSCT by risk, we note that the distribution of cases at the levels of risk was not necessarily consistent from year to year. For example, while transplants done 1998 and earlier were predominantly for leukemia, indications during subsequent years included lymphomas and solid tumors, as well as nonmalignant indications.
Preparative regimen
Subject enrollment was reasonably evenly distributed among the regimens (see Table S4 ) PBSC Myeloablative (220 subjects), PBSC Nonmyeloablative (292 subjects) and TLD + PBSC Nonmyeloablative (226 subjects) preparative regimens, with relatively fewer enrolled on the early Bone Marrow Myeloablative protocols (62 subjects) (Table 1A) .
Pretransplant transfusions
A substantial proportion of the subjects required pretransplant transfusions on Days −10 through −1; among the study population, 44.4% received RBCs, 22.0% received platelets, and 46.4% received one or both components (Table 1A) . This is consistent with these patients having a variety of diagnoses in more than one diagnostic category (see Table S3 ). We note that only 12.3% of all diagnoses were a nonmalignant hematologic disorder (see Table S3 ), including, for example, aplastic anemia, in which patients are RBC transfusion dependent; severe congenital anemias such as SCD, and primary immune deficiency diseases. Patients with SCD constituted 2.8% of all diagnoses, and those with SS hemoglobin received exchange transfusion prior to Day −7 when their preparative regimen was started, if needed, to reduce hemoglobin S levels to 30% or less.
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CD34+ dose
Mean CD34+ dose, for n = 780 subjects with known dose, was 6.79 +/− 3.69 × 10 6 /kg (95% confidence interval, 6.53-7.05 × 10 6 /kg according to the t-distribution). The distribution of subjects with known CD34+ dose into the CD34+ dose categories was similar for "Large Dose" and "Medium Dose," with 405 subjects and 322 subjects, respectively; fewer individuals (53 subjects) received the "Small Dose (Table 1A) ."
ABO for recipient and donor
Among the 800 recipient-donor pairs, most were ABO identical (553; 69.1%), while smaller numbers of patients with major (114; 14.3%), bidirectional (29; 3.6%), and minor (104; 13%) mismatches were transplanted (Table 1A) . (Table 1A) .
Year of transplant
RBC and platelet transfusion events throughout 200 days' follow-up Survival and availability for transfusion
By Day 101, 705 (88%) of 800 subjects remained available for transfusion, and by Day 200, 623 (78%) remained available ( Fig. 1A and Table 1B ). Patients became unavailable for further transfusions upon 1) death or 2) censor due to a second transplant.
Sum of RBC and platelet transfusion events
Of 800 subjects, 706 received RBCs or platelets during followup through 200 days post-HSCT (Table 1B) . For all subjects, RBC transfusion support included 8345 units during Days 0 through 100 and 2246 units during Days 101 through 200, for a total of 10,590 RBC transfusion events (Table S2) . Similarly, there were 10,199 platelet transfusion events.
Quantity of RBC transfusions during intervals
Univariate analyses indicated that CD34+ stem cell dose, need for RBC transfusion before transplant (during the interval Day −10 through Day −1), ABO match of the donor versus recipient, diagnostic category, transplant regimen, and transplant year were all significantly associated with quantity of RBC transfusions for Days 0 through 30 (p ≤ 0.01). For Days 0 through 100, all of these factors, except ABO match, remained significant. Regarding the importance of transplant year, we acknowledge that evolution of transfusion practice guidelines may be contributory, as described above. Importantly, for the interval Days 101 through 200, CD34+ dose was the only factor that remained significant (p = 0.008) ( Table 2) .
Multivariable analyses (Table 3A ) identified factors that were independently associated with quantity of RBC transfusions during 0 to 30 days after HSCT, namely, need for RBC pretransplant, CD34+ dose, year of transplant, diagnostic category, and ABO match. During 0 to 100 days after HSCT, only the need for RBC pretransplant, CD34+ dose, and year of transplant were significant.
Quantity of platelet transfusions during intervals
Univariate analyses indicated that CD34+ stem cell dose, need for platelet transfusion before transplant (during the interval Day −10 through Day −1), diagnostic category, transplant regimen, and year of transplant were significantly The percentage of the total variance among responses (i.e., RBC usage or platelet usage) that is explained by the model. Intercept: The mean value of the outcome among subjects for whom all variables in the model have the reference value. Effect estimate: The difference in the estimated mean associated with that variable or category, versus the reference group, while simultaneously accounting for effects of other factors in the model. F value: The F value measures the degree of evidence that the independent variable improves model fit. F is larger for more improvement of fit. p value: The p value for overall significance of each variable in the model is shown in bold. Nonbolded p values are interpreted differently; they only help assess relative effects among different categories of the same variable (smaller suggests a stronger difference). PBSC = peripheral blood stem cell; RBC = red blood cell; TLD = targeted lymphocyte depletion. associated with quantity of platelet transfusion support for both Days 0 through 30 and Days 0 through 100 at the level of p = 0.01 or less. As noted, regarding the importance of transplant year, we acknowledge that evolution of transfusion practice guidelines may be contributory. Again, importantly, for the interval Days 101 through 200, CD34+ dose was the only factor that remained significant (p = 0.005; Table 2 ).
Multivariable analyses (Table 3B) for quantity of platelet transfusions demonstrated that during both the 0 to 30 days and 0 to 100 days post-HSCT intervals, significant factors were need for platelet support pretransplant, CD34+ dose, year of transplant, and transplant regimen. Since the need for platelet transfusion support declined rapidly during the first 10 days after HSCT (Fig. 1C) , with very few transfusion events during Days 31 through 100, it is reasonable that factors identified as important for platelet transfusion during 0 to 30 days were also important for the longer time interval 0 to 100 days.
Time to RBC transfusion independence
Fully 25% of patients became RBC transfusion independent by Day 5, 50% by Day 15, and 75% by Day 44 (Fig. 1B) . The time course for RBC transfusion independence was compared for factors including the need for RBC transfusion prior to Day 0 ( Fig. 2A), CD34+ dose (Fig. 2B) , and year of transplant (Fig. 2C) . The ABO type of the recipient as compared to the donor was associated with time to RBC transfusion independence (Fig. 3A) , with major mismatches requiring a significantly longer time to achieve freedom from RBC transfusion support, as compared to identical or minor mismatches. For patients transplanted using a nonmyeloablative regimen, those with major mismatches required 1 to 2 months longer to achieve RBC transfusion independence (Fig. 3B ). Multivariable analysis (Table 4A) demonstrated that RBC transfusions prior to Day 0, CD34+ dose category, and ABO mismatch were significant for time to RBC transfusion independence.
Time to platelet transfusion independence
For platelet support, 25% of subjects were transfusion independent at Day 0, 50% become independent by Day 9 and 75% at Day 14 (Fig. 1C) . The time course to achieve independence was very short for most subjects. Overall, this was a more rapid time course than described above for RBCs. Multivariable analysis (Table 4B ) identified the factors that were independently significant for time to platelet transfusion independence: need for platelet transfusions before transplant, diagnostic category, transplant regimen, and the year of the transplant.
DISCUSSION
This report describes the substantial and sustained RBC and platelet transfusion support provided for MSD allogeneic The P value for overall significance of each variable in the model is shown in bold. Nonbolded p values are interpreted differently; they only help assess relative effects among different categories of the same variable (smaller suggests a stronger difference). Hazard ratio: The hazard ratio characterizes the ratio in instantaneous chance of becoming independent relative to those in the reference group; values greater than 1 reflect faster attainment of transfusion independence. CI = confidence interval; PBSC = peripheral blood stem cell; RBC = red blood cell; TLD = targeted lymphocyte depletion.
HSCT transplants for Phase I/II clinical trials conducted from 1993 through 2010 at a single center. While several reports [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] (Table S5 , available as supporting information in the online version of this paper) have examined one or more of the factors that we studied, we have been able to undertake a series of analyses to determine the relative importance of these variables. We include transplants performed continuously over many years, a variety of transplant practices, a substantial number of subjects, and extended follow-up. We have employed two independent and complementary approaches to analysis: quantitation of the number of transfusions needed during intervals of interest after HSCT, and determination of time to transfusion independence. This study confirms the widely accepted experience that ABO incompatibility is a potential complication in allogeneic HSCT. [40] [41] [42] We provide evidence that ABO mismatch is a relatively important variable, even after controlling for the other factors among those examined. Multivariable analysis of factors important for quantity of RBC transfusions during Days 0 through 30 demonstrates the potential importance of major or minor mismatches as compared to identical grafts, with its p value of 0.014 being near our 0.01 cutoff for significance. Further, for all subjects, multivariable analysis of time to RBC transfusion independence clearly demonstrates the importance of major mismatches compared to ABO minor mismatches or identical transplants (p = 0.001). RBC major mismatches required about 10 days longer to reach independence overall (logrank p = 0.005); we also note that the effect appears exaggerated in the setting of nonmyeloablative conditioning, where ABO mismatches required 1 to 2 months longer to achieve transfusion independence (logrank p = 0.004). This and other studies emphasize the need for the transfusion medicine service to carefully assess before HSCT and monitor closely all such patients after HSCT. [23] [24] [25] [26] [27] We provide evidence for the importance of CD34+ dose on the quantity and time course of transfusion support following HSCT. A broad range of CD34+ doses were available for analysis. Although the more historic cases in our data set were bone marrow transplants, and laboratory methods for determination of CD34+ stem cell content were in development in the early 1990s, 43, 44 CD34+ stem cell doses were determined for grafts continuously using contemporary methods at our center. As described here, it is especially noteworthy that beyond 100 days after HSCT, the only factor of importance for quantity of RBCs and platelets transfused, among those we examined, was the CD34+ dose. Multiple factors were important for quantity of RBC and platelet transfusion support during the first 30 days after HSCT; those that retained importance through 100 days after HSCT included the CD34+ stem cell dose of the graft received, the need for transfusions during the 10 days preceding the day of graft infusion, and the transplant year. These data confirm that "small" CD34+ doses (<2 × 10 6 /kg) were independently associated with seriously compromised marrow recovery, as judged by the need for increased RBC and platelet transfusion and prolonged time to RBC transfusion independence.
Somewhat unexpectedly, we demonstrate that pre-HSCT transfusion is an important predictor of both quantity of components needed post-HSCT, and time to independence of transfusion support. This group included some diagnoses such as aplastic anemia with transfusion dependence due to inability to produce autologous red blood cells. Additionally, many patients in this study received extensive prior chemotherapy or radiation treatment for malignancy, which may have compromised the stem cell niche (see Fig. 2.2 in ref. 45) . The stem cell niche may be important for engraftment and recovery of hematopoietic activity after HSCT. [46] [47] [48] [49] We observed that independence of platelet transfusion support was attained more rapidly, as compared to independence of RBC transfusions. Perhaps this is related to differences in the growth conditions permissive for lineage-committed megakaryocyte progenitors and production of mature platelets, as compared to erythroid progenitors and development of fully differentiated RBC.
This cohort was composed solely of HLA MSDs, and we have focused our analysis on the relative importance of key baseline variables readily available to the transfusion medicine service. We have not examined the impact of acute graft-versus-host disease (GVHD) incidence, its prophylaxis, or treatment as a factor for transfusion support. For a series of National Heart, Lung and Blood Institute myeloablative transplants (excluding chronic leukemias) that included the cases evaluated in this study of transfusion support, acute GVHD Grade II to IV was reported to be 42%, while grade III to IV was 14%.
14 Contemporary HSCT practice utilizes hematopoietic stem cells from HLAmatched and -mismatched donors and cord blood units as well as partially matched related donors (e.g., haploidentical). These sources may have greater major or minor histoincompatibility and greater potential for GVHD as compared to MSDs. Acute GVHD occurring 100 or more days after HSCT may increase the need for transfusion for those individuals with involvement of the mucosa of the gastrointestinal tract. Other post-HSCT complications such as autoimmune hemolytic anemia or immune thrombocytopenia may also contribute to the need for transfusion support. These are subjects for future analyses.
In conclusion, in this retrospective study, we describe several clinical factors associated with quantity of RBC and platelet transfusion support and/or time to transfusion independence after MSD allogeneic HSCT. Low doses of CD34+ stem cells and ABO mismatch of the graft, and a requirement for transfusion support before HSCT due to marrow damage caused by disease or by chemotherapy used for treatment of the primary disease, are associated with impaired recovery of hematopoiesis following transplantation. This information should help to identify patients likely to have unusual or potentially urgent transfusion needs after HSCT and plan prospectively for best patient care and maintenance of component inventory. We hope this report will assist with the management of such patients.
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